Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard?of?care TKIs in Phase III trial for newly diagnosed patients…

MEDIA & INVESTOR RELEASE

Excerpt from:
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard?of?care TKIs in Phase III trial for newly diagnosed patients...

Related Posts